Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the <scp>ALLEGRO</scp> clinical development programme
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
Gain-of-function human <i>UNC93B1</i> variants cause systemic lupus erythematosus and chilblain lupus
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Landscape of mast cell populations across organs in mice and humans
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase <scp>IIIb</scp> randomized, double‐blind, parallel‐group, <scp>GUIDE</scp> study
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials
<b>Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohort</b><scp>PSOBIOTEQ</scp>
Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bimekizumab versus Secukinumab in Plaque Psoriasis
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics
Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis
<i>De novo</i> psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort
The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force
European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis
European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect
Therapeutic patient education and self‐management support for patients with psoriasis – a systematic review
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)